Table 1 Patient and disease characteristics
Age | Â |
|---|---|
Median (range), years | 61 (46–83) |
Gender, n (%) | |
Female | 10 (14) |
Male | 61 (86) |
Smoking status | |
Never smoker | 5 (11) |
Previous smoker | 12 (26) |
Current smoker | 29 (63) |
Missing data | 25 |
Karnofsky performance status | |
Median (range) | 90 (60–100) |
 > 70, n (%) | 60 (85) |
 ≤ 70, n (%) | 11 (15) |
Oncological resection of primary tumor | |
Yes | 8 (11) |
No | 63 (89) |
Induction chemotherapy | |
Yes | 7 (10) |
No | 64 (90) |
Concomitant systemic therapy | |
None | 9 (13) |
Cisplatin or carboplatin | 50 (77) |
Cetuximab | 12 (17) |
Site of primary tumor, n (%) | |
Oral cavity | 6 (8) |
Oropharynx | 28 (39) |
Hypopharynx | 19 (27) |
Larynx | 14 (20) |
Multicompartmental | 4 (6) |
UICC stage, n (%) | |
II | 2 (3) |
III | 11 (16) |
IV | 58 (81) |
Tumor grade, n (%) | |
G1 | 1 (1) |
G2 | 38 (54) |
G3 | 32 (45) |
Metabolic tumor volume, MTV (cc) | |
Median (range) | 6.5 (1.7–43) |
Standard uptake value, SUVmax | |
Median (range) | 15.7 (4.2–34.3) |
Tumor lesion glycolysis, TLG | |
Median (range) | 54 (8–471) |
Neutrophil-to-lymphocyte ratio, NLR | |
Median (range) | 3.47 (0.8–19.8) |
Platelet-to-lymphocyte ratio, PLR | |
Median (range) | 195 (59–951) |